Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-10-01T00:00:00.000Z

Sentiment: neutral

Topics: corporate-filing, pharmaceuticals

Related Tickers: CPRX

TL;DR

CATALYST PHARMACEUTICALS FILED AN 8-K ON 10/1/25. CHECK FOR UPDATES.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is based in Coral Gables, Florida, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates Catalyst Pharmaceuticals is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing reporting corporate events and financial statements, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Catalyst Pharmaceuticals in this 8-K?

The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the provided text snippet.

What is the SIC code for Catalyst Pharmaceuticals?

The Standard Industrial Classification (SIC) code for Catalyst Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.

When was Catalyst Pharmaceuticals, Inc. previously known as Catalyst Pharmaceutical Partners, Inc.?

The company was formerly known as Catalyst Pharmaceutical Partners, Inc. with a date of name change on February 15, 2011.

What is the fiscal year end for Catalyst Pharmaceuticals?

The fiscal year end for Catalyst Pharmaceuticals is December 31 (1231).

What is the primary exchange where Catalyst Pharmaceuticals' stock is traded?

Catalyst Pharmaceuticals' stock is traded on NASDAQ, as indicated by the filing.

From the Filing

0001193125-25-226837.txt : 20251001 0001193125-25-226837.hdr.sgml : 20251001 20251001163113 ACCESSION NUMBER: 0001193125-25-226837 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251001 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251001 DATE AS OF CHANGE: 20251001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 251365049 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d118298d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-10-01 2025-10-01     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 1, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On October 1, 2025, the Company issued a press release announcing that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $200 million of its common stock between October 1, 2025 and December 31, 2026. Repurchases under the new share repurchase program may be made through a variety of methods, including ope

View on Read The Filing